Literature DB >> 25127731

Interest in genetic testing in Ashkenazi Jewish Parkinson's disease patients and their unaffected relatives.

Manisha Gupte1, Roy N Alcalay, Helen Mejia-Santana, Deborah Raymond, Rachel Saunders-Pullman, Ernest Roos, Martha Orbe-Reily, Ming-X Tang, Anat Mirelman, Laurie Ozelius, Avi Orr-Urtreger, Lorraine Clark, Nir Giladi, Susan Bressman, Karen Marder.   

Abstract

Our objective was to explore interest in genetic testing among Ashkenazi Jewish (AJ) Parkinson's Disease (PD) cases and first-degree relatives, as genetic testing for LRRK2 G2019S is widely available. Approximately 18 % of AJ PD cases carry G2019S mutations; penetrance estimations vary between 24 and 100 % by age 80. A Genetic Attitude Questionnaire (GAQ) was administered at two New York sites to PD families unaware of LRRK2 G2019S mutation status. The association of G2019S, age, education, gender and family history of PD with desire for genetic testing (outcome) was modeled using logistic regression. One-hundred eleven PD cases and 77 relatives completed the GAQ. Both PD cases and relatives had excellent PD-specific genetic knowledge. Among PD, 32.6 % "definitely" and 41.1 % "probably" wanted testing, if offered "now." Among relatives, 23.6 % "definitely" and 36.1 % "probably" wanted testing "now." Desire for testing in relatives increased incrementally based on hypothetical risk of PD. The most important reasons for testing in probands and relatives were: if it influenced medication response, identifying no mutation, and early prevention and treatment. In logistic regression, older age was associated with less desire for testing in probands OR = 0.921 95%CI 0.868-0.977, p = 0.009. Both probands and relatives express interest in genetic testing, despite no link to current treatment or prevention.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25127731      PMCID: PMC4331260          DOI: 10.1007/s10897-014-9756-x

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  16 in total

1.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Authors:  E Sidransky; M A Nalls; J O Aasly; J Aharon-Peretz; G Annesi; E R Barbosa; A Bar-Shira; D Berg; J Bras; A Brice; C-M Chen; L N Clark; C Condroyer; E V De Marco; A Dürr; M J Eblan; S Fahn; M J Farrer; H-C Fung; Z Gan-Or; T Gasser; R Gershoni-Baruch; N Giladi; A Griffith; T Gurevich; C Januario; P Kropp; A E Lang; G-J Lee-Chen; S Lesage; K Marder; I F Mata; A Mirelman; J Mitsui; I Mizuta; G Nicoletti; C Oliveira; R Ottman; A Orr-Urtreger; L V Pereira; A Quattrone; E Rogaeva; A Rolfs; H Rosenbaum; R Rozenberg; A Samii; T Samaddar; C Schulte; M Sharma; A Singleton; M Spitz; E-K Tan; N Tayebi; T Toda; A R Troiano; S Tsuji; M Wittstock; T G Wolfsberg; Y-R Wu; C P Zabetian; Y Zhao; S G Ziegler
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

2.  Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.

Authors:  Stefano Goldwurm; Sara Tunesi; Silvana Tesei; Michela Zini; Francesca Sironi; Paola Primignani; Corrado Magnani; Gianni Pezzoli
Journal:  Mov Disord       Date:  2011-06-28       Impact factor: 10.338

3.  Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.

Authors:  Joanne Trinh; Rim Amouri; John E Duda; James F Morley; Matthew Read; Alan Donald; Carles Vilariño-Güell; Christina Thompson; Chelsea Szu Tu; Emil K Gustavsson; Samia Ben Sassi; Emna Hentati; Mourad Zouari; Emna Farhat; Fatma Nabli; Faycel Hentati; Matthew J Farrer
Journal:  Neurobiol Aging       Date:  2013-11-22       Impact factor: 4.673

4.  Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease.

Authors:  Nir Giladi; Anat Mirelman; Avner Thaler; Anat Bar-Shira; Tanya Gurevich; Avi Orr-Urtreger
Journal:  J Neurol Sci       Date:  2011-06-25       Impact factor: 3.181

5.  Knowledge of and interest in genetic results among Parkinson disease patients and caregivers.

Authors:  Karina Sakanaka; Cheryl H Waters; Oren A Levy; Elan D Louis; Wendy K Chung; Karen S Marder; Roy N Alcalay
Journal:  J Genet Couns       Date:  2013-06-09       Impact factor: 2.537

6.  Genetic testing and Parkinson disease: assessment of patient knowledge, attitudes, and interest.

Authors:  Dana Clay Falcone; Elisabeth McCarty Wood; Sharon X Xie; Andrew Siderowf; Vivianna M Van Deerlin
Journal:  J Genet Couns       Date:  2011-04-08       Impact factor: 2.537

7.  Fear of health insurance loss among individuals at risk for Huntington disease.

Authors:  Emily Oster; E Ray Dorsey; Jan Bausch; Aileen Shinaman; Elise Kayson; David Oakes; Ira Shoulson; Kimberly Quaid
Journal:  Am J Med Genet A       Date:  2008-08-15       Impact factor: 2.802

8.  Interest in predictive testing for Parkinson's disease: impact of neuroprotective therapy.

Authors:  N Dahodwala; J Connolly; J Farmer; M B Stern; D Jennings; A Siderowf
Journal:  Parkinsonism Relat Disord       Date:  2007-04-20       Impact factor: 4.891

9.  The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Authors:  A Orr-Urtreger; C Shifrin; U Rozovski; S Rosner; D Bercovich; T Gurevich; H Yagev-More; A Bar-Shira; N Giladi
Journal:  Neurology       Date:  2007-10-16       Impact factor: 9.910

10.  Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.

Authors:  Roy N Alcalay; Anat Mirelman; Rachel Saunders-Pullman; Ming-X Tang; Helen Mejia Santana; Deborah Raymond; Ernest Roos; Martha Orbe-Reilly; Tanya Gurevich; Anat Bar Shira; Mali Gana Weisz; Kira Yasinovsky; Maayan Zalis; Avner Thaler; Andres Deik; Matthew James Barrett; Jose Cabassa; Mark Groves; Ann L Hunt; Naomi Lubarr; Marta San Luciano; Joan Miravite; Christina Palmese; Rivka Sachdev; Harini Sarva; Lawrence Severt; Vicki Shanker; Matthew Carrington Swan; Jeannie Soto-Valencia; Brooke Johannes; Robert Ortega; Stanley Fahn; Lucien Cote; Cheryl Waters; Pietro Mazzoni; Blair Ford; Elan Louis; Oren Levy; Llency Rosado; Diana Ruiz; Tsvyatko Dorovski; Michael Pauciulo; William Nichols; Avi Orr-Urtreger; Laurie Ozelius; Lorraine Clark; Nir Giladi; Susan Bressman; Karen S Marder
Journal:  Mov Disord       Date:  2013-10-15       Impact factor: 10.338

View more
  7 in total

1.  Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium.

Authors:  Karen Marder; Yuanjia Wang; Roy N Alcalay; Helen Mejia-Santana; Ming-Xin Tang; Annie Lee; Deborah Raymond; Anat Mirelman; Rachel Saunders-Pullman; Lorraine Clark; Laurie Ozelius; Avi Orr-Urtreger; Nir Giladi; Susan Bressman
Journal:  Neurology       Date:  2015-06-10       Impact factor: 9.910

2.  Parkinson's Disease: Patients' Knowledge, Attitudes, and Interest in Genetic Counseling.

Authors:  Kristin A Maloney; Dina S Alaeddin; Rainer von Coelln; Shannan Dixon; Lisa M Shulman; Katrina Schrader; Yue Guan
Journal:  J Genet Couns       Date:  2018-03-02       Impact factor: 2.537

3.  Motivation, Perception, and Treatment Beliefs in the Myocardial Infarction Genes (MI-GENES) Randomized Clinical Trial.

Authors:  Sharma Kattel; Tochukwu Onyekwelu; Sherry-Ann Brown; Hayan Jouni; Erin Austin; Iftikhar J Kullo
Journal:  J Genet Couns       Date:  2017-04-06       Impact factor: 2.537

4.  Disclosure of research results in genetic studies of Parkinson's disease caused by LRRK2 mutations.

Authors:  Claustre Pont-Sunyer; Susan Bressman; Deborah Raymond; Amanda Glickman; Eduardo Tolosa; Rachel Saunders-Pullman
Journal:  Mov Disord       Date:  2015-05-07       Impact factor: 10.338

Review 5.  Therapy of Parkinson's Disease Subtypes.

Authors:  Connie Marras; K Ray Chaudhuri; Nataliya Titova; Tiago A Mestre
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

6.  Attitudes Toward Genetic Testing for Celiac Disease.

Authors:  Abhik Roy; Michele Pallai; Benjamin Lebwohl; Annette K Taylor; Peter H Green
Journal:  J Genet Couns       Date:  2015-08-02       Impact factor: 2.537

7.  Patient Knowledge and Attitudes towards Genetic Testing in Parkinson's Disease Subjects with Deep Brain Stimulation.

Authors:  Avram Fraint; Bichun Ouyang; Leonard Verhagen Metman; Carolyn Jones; Deborah A Hall; Karen Marder; Gian Pal
Journal:  Parkinsons Dis       Date:  2019-04-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.